Login to Your Account

Panel to Weigh Effectiveness, Risks

FDA: Avastin Fails to Prolong Life in Breast Cancer Patients

By Donna Young

Wednesday, December 5, 2007
While the addition of Genentech's Avastin (bevacizumab) to the chemotherapy agent paclitaxel slowed the progression of tumors in women with metastatic breast cancer, it did not prolong the patients' overall survival and increased their risk of adverse events and death, drug regulators said. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription